会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • METHOD FOR DETERMINATION OF OXIDATIVE STRESS
    • 用于确定氧化应力的方法
    • US20090029409A1
    • 2009-01-29
    • US12161203
    • 2007-01-16
    • Tomoyoshi SogaMakoto Suematsu
    • Tomoyoshi SogaMakoto Suematsu
    • C12Q1/06
    • G01N33/6893G01N2430/00G01N2500/00G01N2800/00
    • Provided is a biomarker that enables easy and rapid detection of oxidative stress on a living organism and enables prevention of tissue damage or cell necrosis by drug administration, and which is a powerful marker for the study of toxicity and pharmacokinetics of various agents. Oxidative stress is determined by measuring blood concentration of ophthalmic acid, which is a substance that varies in blood depending on the variation of reduced glutathione (GSH) concentration in a biological sample with the use of an analyzer such as a capillary electrophoresis-mass spectrometer. Further, an anti-oxidative stress agent is screened by administering an anti-oxidative stress candidate agent to a non-human animal under oxidative stress conditions, measuring blood concentration of ophthalmic acid, and evaluating the degree of decrease in the ophthalmic acid concentration.
    • 提供了能够容易且快速地检测活体上的氧化应激的生物标志物,并且能够通过药物给药预防组织损伤或细胞坏死,并且其是研究各种药剂的毒性和药代动力学的有力标记。 通过使用诸如毛细管电泳 - 质谱仪的分析仪,通过测量根据生物样品中还原型谷胱甘肽(GSH)浓度的变化的血液变化的眼睛液的血液浓度来测定氧化应激。 此外,通过在氧化应激条件下向非人动物施用抗氧化应激候选试剂,测定眼酸的血药浓度,评价眼酸浓度的降低程度来筛选抗氧化应激剂。
    • 6. 发明授权
    • Method for determination of oxidative stress
    • 氧化应激测定方法
    • US07964177B2
    • 2011-06-21
    • US12161203
    • 2007-01-16
    • Tomoyoshi SogaMakoto Suematsu
    • Tomoyoshi SogaMakoto Suematsu
    • A61K49/00G01N33/00
    • G01N33/6893G01N2430/00G01N2500/00G01N2800/00
    • Provided is a biomarker that enables easy and rapid detection of oxidative stress on a living organism and enables prevention of tissue damage or cell necrosis by drug administration, and which is a powerful marker for the study of toxicity and pharmacokinetics of various agents. Oxidative stress is determined by measuring blood concentration of ophthalmic acid, which is a substance that varies in blood depending on the variation of reduced glutathione (GSH) concentration in a biological sample with the use of an analyzer such as a capillary electrophoresis-mass spectrometer. Further, an anti-oxidative stress agent is screened by administering an anti-oxidative stress candidate agent to a non-human animal under oxidative stress conditions, measuring blood concentration of ophthalmic acid, and evaluating the degree of decrease in the ophthalmic acid concentration.
    • 提供了能够容易且快速地检测活体上的氧化应激的生物标志物,并且能够通过药物给药预防组织损伤或细胞坏死,并且其是研究各种药剂的毒性和药代动力学的有力标记。 通过使用诸如毛细管电泳 - 质谱仪的分析仪,通过测量根据生物样品中还原型谷胱甘肽(GSH)浓度的变化的血液变化的眼睛液的血液浓度来测定氧化应激。 此外,通过在氧化应激条件下向非人动物施用抗氧化应激候选试剂,测定眼酸的血药浓度,评价眼酸浓度的降低程度来筛选抗氧化应激剂。
    • 8. 发明申请
    • Method for Predicting the Migration Time of Ionic Compounds by Electrophoretic Measurement
    • 通过电泳测量预测离子化合物的迁移时间的方法
    • US20070256935A1
    • 2007-11-08
    • US11660676
    • 2005-08-24
    • Masahiro SugimotoTomoyoshi SogaMasaru Tomita
    • Masahiro SugimotoTomoyoshi SogaMasaru Tomita
    • B01D57/02
    • G01N27/447
    • When the migration time of a low molecular weight compound having an unknown migration time in microchip electrophoresis, capillary electrophoresis, or a capillary electrophoresis mass spectrometer is predicted, first, with respect to a substance having a known electrophoretic migration time, characteristic quantities (descriptors) thereof which can be numerically expressed from a structure thereof are computed to predict the relation between the characteristic quantities (descriptors) and the migration time; the migration times of some substances are measured by electrophoresis or an electrophoresis mass spectrometer to learn about the relation; and using the learnt result, the migration time of the substance having an unknown migration time in the electrophoresis or electrophoresis mass spectrometer is predicted from the structure thereof.
    • 当预测在微芯片电泳,毛细管电泳或毛细管电泳质谱仪中具有未知迁移时间的低分子量化合物的迁移时间时,首先,关于具有已知电泳迁移时间的物质,特征量(描述符) 计算其数值表示的结构,以预测特征量(描述符)与迁移时间之间的关系; 通过电泳或电泳质谱仪测量某些物质的迁移时间,以了解关系; 并且使用所获得的结果,从其结构可以预测在电泳或电泳质谱仪中具有未知迁移时间的物质的迁移时间。
    • 9. 发明授权
    • Human renal disease marker substance
    • 人类肾脏疾病标志物质
    • US08709816B2
    • 2014-04-29
    • US13393091
    • 2010-09-03
    • Takaaki AbeTomoyoshi Soga
    • Takaaki AbeTomoyoshi Soga
    • G01N33/48G01N33/00
    • G01N33/6893G01N2800/347
    • The present invention relates to a method for diagnosing, and treating renal disease in a patient by having a test performed for detecting or quantifying one or more renal disease markers present in a test blood sample from the patient; and administering treatment to improve renal function. In particular embodiments, the test performed quantifies cis-aconitate, and the patient is identified as having the renal disease when a concentration of cis-aconitate present in the patient's test blood sample is higher than that of a control. Methods of the present invention can allow diagnosis and treatment of patients with early stage renal disease, such as early stage renal failure. Another aspect of the present invention relates to methods for screening for a prophylactic/therapeutic agent for treating renal disease using one or more renal disease markers.
    • 本发明涉及通过进行用于检测或定量来自患者的测试血液样品中存在的一种或多种肾脏疾病标志物的测试来诊断和治疗患者的肾脏疾病的方法; 并进行治疗以改善肾功能。 在具体实施方案中,进行的测试量化顺式乌头酸,并且当患者测试血液样品中存在的顺式乌头酸浓度高于对照组时,患者被鉴定为具有肾脏疾病。 本发明的方法可以允许诊断和治疗患有早期肾病的早期肾衰竭患者。 本发明的另一方面涉及使用一种或多种肾脏疾病标记物筛选用于治疗肾脏疾病的预防/治疗剂的方法。
    • 10. 发明授权
    • Method for determination of oxidative stress
    • 氧化应激测定方法
    • US08309056B2
    • 2012-11-13
    • US13092420
    • 2011-04-22
    • Tomoyoshi SogaMakoto Suematsu
    • Tomoyoshi SogaMakoto Suematsu
    • A61K49/00G01N33/48G01N33/00
    • G01N33/6893G01N2430/00G01N2500/00G01N2800/00
    • Provided is a biomarker that enables easy and rapid detection of oxidative stress on a living organism and enables prevention of tissue damage or cell necrosis by drug administration, and which is a powerful marker for the study of toxicity and pharmacokinetics of various agents. Oxidative stress is determined by measuring blood concentration of ophthalmic acid, which is a substance that varies in blood depending on the variation of reduced glutathione (GSH) concentration in a biological sample with the use of an analyzer such as a capillary electrophoresis-mass spectrometer. Further, an anti-oxidative stress agent is screened by administering an anti-oxidative stress candidate agent to a non-human animal under oxidative stress conditions, measuring blood concentration of ophthalmic acid, and evaluating the degree of decrease in the ophthalmic acid concentration.
    • 提供了能够容易且快速地检测活体上的氧化应激的生物标志物,并且能够通过药物给药预防组织损伤或细胞坏死,并且其是研究各种药剂的毒性和药代动力学的有力标记。 通过使用诸如毛细管电泳 - 质谱仪的分析仪,通过测量根据生物样品中还原型谷胱甘肽(GSH)浓度的变化的血液变化的眼睛液的血液浓度来测定氧化应激。 此外,通过在氧化应激条件下向非人动物施用抗氧化应激候选试剂,测定眼酸的血药浓度,评价眼酸浓度的降低程度来筛选抗氧化应激剂。